Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Abroad (travel likely)RecruitingPHASE2

Conditions

Chronic Myeloid Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

MD Anderson Cancer Center, Houston, Texas, United States
Contact: Study coordinator (Elias Jabbour, MD) · ejabbour@mdanderson.org · 713-792-4764
Contact: Principal Investigator (Elias Jabbour, MD)

Study leads

Elias Jabbour, MD
Principal Investigator
M.D. Anderson Cancer Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.

Chronic Myeloid Leukemia (CML)

Abroad (travel likely)RecruitingPHASE2

Bordeaux, France · Lille, France

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Acute Leukemia of Ambiguous Lineage · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE2

Seattle, United States

Second STOP After Pioglitazone Priming in CML Patients

Chronic Myeloid Leukemia (CML)

Abroad (travel likely)RecruitingPHASE2

Le Chesnay, France · Le Kremlin-Bicêtre, France

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

B-Cell Lymphoma · Myelodysplastic Syndromes (MDS) · Acute Myeloid Leukemia (AML)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Houston, United States